Episode 59: Using Tau to Target Alzheimer’s

Our top five episodes of the year.

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.

Sanjeev Luther, president and CEO of Rafael Pharmaceuticals, discusses how he managed to turn around a company on the brink of bankruptcy and advance clinical trials for its lead cancer drug through COVID-19.

In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.

Tim Walbert, CEO of Horizon Therapeutics, shares his unique perspective on managing a company through COVID-19, in light of the fact that he himself is immunocompromised.

Dr. Jonathan Gertler, CEO of Back Bay Life Science Advisors, and Dr. Stephan Gauldie, Senior Vice President of Back Bay, talk about the new guidelines set forth by FDA in regard to gene therapy, and what those new parameters mean for pharma and biotech.